Researchers at Kumamoto University in Japan are reporting a promising advance that could one day replace injections for many people with diabetes with an oral option. Scientists have announced progress toward an insulin pill designed to lower blood sugar without the need for needle sticks.

The finding marks a potential turning point in how the condition is managed, offering a non invasive route that could improve adherence and quality of life for patients.

Insulin injections remain a daily burden for many patients, said Associate Professor Shingo Ito, a lead investigator in the study.

Our peptide-based platform offers a new route to deliver insulin orally, and may be applicable to long-acting insulin formulations and other injectable biologics.

The study, published in Molecular Pharmaceutics, tested the delivery of oral insulin by constructing a carrier peptide called DNP-V.

The researchers aimed to overcome the long standing barrier that prevents most protein drugs from being absorbed intact through the gastrointestinal tract.

A key idea was to use DNP-V to shuttle insulin through the small intestine where the absorption of protein drugs is typically poor.

In diabetic mice, the team administered the peptide by mouth with zinc stabilized insulin. The insulin was formulated with zinc ions to enhance its stability, according to the report.

The results showed a rapid and significant drop in blood glucose, with a sustained reduction over time. In the animal models, blood sugar levels fell toward normal ranges and stayed there for a meaningful period after a single dose.

When DNP-V was attached directly to insulin, the team observed an improvement in intestinal absorption along with a similar glucose lowering effect.

The findings suggest that co developed carrier systems can improve the oral uptake of large molecules and yield clinically relevant effects.

The treatment proved effective across different diabetes models, notably reducing post meal glucose spikes with only one daily dose, which could simplify regimens for patients who currently rely on multiple daily injections.

The authors concluded that DNP peptides could serve as flexible and adaptable platforms for delivering large molecule drugs by mouth. This work shows that a peptide based delivery system may offer a practical path to oral formulations of something once confined to injections.

This technology can simply and effectively convert injectable biopharmaceuticals into orally administrable forms, offering a promising path to practical, patient friendly oral therapies, the researchers wrote.

The researchers acknowledge that while the results in mice are encouraging, they do not guarantee the same outcomes in humans. More studies are needed to establish safety, dosing, and efficacy in people, particularly over longer periods and in diverse populations.

Experts not involved in the work cautioned that while optimism is warranted, translating from animals to humans will require careful, rigorous testing.

The road to an approved oral insulin therapy remains long, but the approach represents a credible path forward, reflecting ongoing innovation in drug delivery.

Insulin use, especially in type 1 diabetes, is sometimes difficult to regulate by injection. Oral use would have major advantages. This is very promising provided that it works in humans, which is a big ‘if’.